1. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
  2. HSP

Alvespimycin (Synonyms: 17-DMAG; KOS-1022; NSC 707545)

Cat. No.: HY-10389
Handling Instructions

Alvespimycin (17-DMAG; KOS-1022; NSC 707545) is a potent, water-soluble HSP90 inhibitor with IC50 of 62 nM.

For research use only. We do not sell to patients.
Alvespimycin Chemical Structure

Alvespimycin Chemical Structure

CAS No. : 467214-20-6

Size Price Stock
1 mg USD 60 Get quote

* Please select Quantity before adding items.

Other In-stock Forms of Alvespimycin:

Customer Review

Other Forms of Alvespimycin:

    Alvespimycin purchased from MCE. Usage Cited in: Friedrich-Alexander University Erlangen-Nuremberg. 2016.

    pJAK2 and JAK2 expression upon TGFβ stimulation and JAK inhibitors incubation. pJAK2 and JAK2 expression in healthy human fibroblasts after stimulation with TGFβ for 3 days and incubation with TG101209, 17-DMAG or Ruxolitinib.
    • Biological Activity

    • Protocol

    • Technical Information

    • References

    Description

    Alvespimycin (17-DMAG; KOS-1022; NSC 707545) is a potent, water-soluble HSP90 inhibitor with IC50 of 62 nM. IC50 Value: 62 nM Target: HSP90 in vitro: 17-DMAG displays ~2 times potency against human Hsp90 than 17-AAG, with IC50 of 62 nM versus 119 nM. In SKBR3 and SKOV3 cells which over-express Hsp90 client protein Her2, 17-DMAG causes down-regulation of Her2 with EC50 of 8 nM and 46 nM, respectively, as well as induction of Hsp70 with EC50 of 4 nM and 14 nM, respectively, leading to significant cytotoxicity with GI50 of 29 nM and 32 nM, respectively, consistent with Hsp90 inhibition. 17-DMAG in combination with vorinostat synergistically induces apoptosis of the cultured MCL cells as well as primary MCL cells, more potently than either agent alone, by markedly attenuating the levels of cyclin D1 and CDK4, as well as of c-Myc, c-RAF and Akt. in vivo: 17-DMAG treatment at 5 mg/kg or 25 mg/kg thrice per week significantly reduces tumor growth of TMK-1 xenografts, by significantly reducing vessel area and numbers of proliferating tumor cells in sections. Consistent the inhibition of FAK signaling in vivo, 17-DMAG treatment at 25 mg/kg three times a week significantly suppresses tumor growth, and metastasis of ME180 and SiHa xenografts in mice. Administration of 17-DMAG at 10 mg/kg for 16 days significantly decreases the white blood cell count and prolongs the survival in a TCL1-SCID transplant mouse model.

    Clinical Trial
    View MoreCollapse
    References
    Molecular Weight

    616.75

    Formula

    C₃₂H₄₈N₄O₈

    CAS No.

    467214-20-6

    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.

    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Alvespimycin
    Cat. No.:
    HY-10389
    Quantity: